Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-12-11

Clinical Trial Update: Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA [Phase 2]

View source ↗

Summary

Phase 2 trial results for PP405 in adults with androgenetic alopecia, detailing safety, pharmacokinetics, and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • PP405

Snippet

Sponsor: Pelage Pharmaceuticals, Inc. | Conditions: Androgenetic Alopecia | Phase 2 | Status: COMPLETED